A Phase 1 interventional study of FV-100 in Acute Herpes Zoster, sponsored by ContraVir Pharmaceuticals, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-01.
Sponsored by ContraVir Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
This study is designed to evaluate the potential for a PK drug-drug interaction between FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.
Inclusion Criteria:
Exclusion Criteria:(must NOT meet the following)
FV-100 400mg OD as a single dose fasted (\>/= 8 hours)
Drug: FV-100
FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (\>/= 8 hours)
Drug: FV-100
Subjects will be randomized to one of two treatment sequences: AB or BA.
The evaluation of safety of a single oral dose of FV-100 alone and when combined with a single oral dose of ritonavir
Measuring the Cmax, Tmax and AUC for FV-100 pk profile
Time frame: Two weeks
The evaluation of the pharmacokinetics of FV-100 and CF-1743 following a single oral dose of FV-100 administered alone and with a single oral dose of ritonavir
Measuring the Cmax, Tmax and AUC for FV-100 pk profile when dosed with ritonavir
Time frame: Two weeks
No study locations are listed for this record.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ContraVir Pharmaceuticals, Inc.